Insider · CIK 0001256708
Mark Andrew Sherman
officer
Files at DLB (Dolby Laboratories, Inc.). First filing Dec 18, 2024, latest Jun 6, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 4
$0 bought, $5.5M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
DLB: Dolby Laboratories, Inc.
DLBOct 9, 2026 · close 58.74
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 18Weak | Dolby Laboratories, Inc. | $1.1M 15,000 shares | -19% | +10% from low-13% from high | |
| 8Weak | Dolby Laboratories, Inc. | $26k 350 shares | -1% | +8% from low-14% from high | |
| 30Weak | Dolby Laboratories, Inc. | $3.4M 40,000 shares | -39% | - | |
| 9Weak | Dolby Laboratories, Inc. | $963k 12,338 shares | -17% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 15, 2026 | DLB Dolby Laboratories, Inc. | AGrant or award Class A Common Stock | +48,076 | $0.00 | $0 | 119,024 | 25 d ago |
| Jun 4, 2025 | DLB Dolby Laboratories, Inc. | MOption exercise Class A Common Stock10b5-1 | +15,000 | $64.60 | $969k | 77,397 | Jun 6, 2025 |
| Jun 4, 2025 | DLB Dolby Laboratories, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -15,000 | $75.02 | $1.1M | 62,397 | Jun 6, 2025 |
| Jun 4, 2025 | DLB Dolby Laboratories, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 4,500 | Jun 6, 2025 |
| May 30, 2025 | DLB Dolby Laboratories, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -350 | $74.97 | $26k | 62,397 | Jun 3, 2025 |
| Jan 30, 2025 | DLB Dolby Laboratories, Inc. | MOption exercise Class A Common Stock10b5-1 | +40,000 | $62.32 | $2.5M | 102,397 | Feb 3, 2025 |
| Jan 30, 2025 | DLB Dolby Laboratories, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -15,000 | $83.00 | $1.2M | 87,397 | Feb 3, 2025 |
| Jan 30, 2025 | DLB Dolby Laboratories, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -25,000 | $86.00 | $2.2M | 62,397 | Feb 3, 2025 |
| Jan 30, 2025 | DLB Dolby Laboratories, Inc. | MOption exercise Employee Stock Option (Right to Buy)derivative10b5-1 | -40,000 | $0.00 | $0 | 16,000 | Feb 3, 2025 |
| Dec 16, 2024 | DLB Dolby Laboratories, Inc. | AGrant or award Class A Common Stock10b5-1 | +20,085 | $0.00 | $0 | 78,410 | Dec 18, 2024 |
| Dec 16, 2024 | DLB Dolby Laboratories, Inc. | MOption exercise Class A Common Stock10b5-1 | +5,192 | $0.00 | $0 | 83,602 | Dec 18, 2024 |
| Dec 16, 2024 | DLB Dolby Laboratories, Inc. | FTax withholding Class A Common Stock10b5-1 | -8,867 | $79.18 | $702k | 74,735 | Dec 18, 2024 |
| Dec 17, 2024 | DLB Dolby Laboratories, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -4,625 | $77.83 | $360k | 70,110 | Dec 18, 2024 |
| Dec 17, 2024 | DLB Dolby Laboratories, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -7,713 | $78.22 | $603k | 62,397 | Dec 18, 2024 |
| Dec 16, 2024 | DLB Dolby Laboratories, Inc. | AGrant or award Performance-Based Restricted Stock Unitderivative10b5-1 | +10,042 | $0.00 | $0 | 10,042 | Dec 18, 2024 |
| Dec 16, 2024 | DLB Dolby Laboratories, Inc. | AGrant or award Employee Stock Option (Right to Buy)derivative10b5-1 | +35,307 | $0.00 | $0 | 35,307 | Dec 18, 2024 |
| Dec 16, 2024 | DLB Dolby Laboratories, Inc. | MOption exercise Performance-Based Restricted Stock Unitderivative10b5-1 | -5,192 | $0.00 | $0 | 0 | Dec 18, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.